Format

Send to

Choose Destination
Methods Mol Biol. 2016;1303:281-97. doi: 10.1007/978-1-4939-2627-5_17.

Next Generation Sequencing in Alzheimer's Disease.

Author information

1
Platform for Genome Analytics, Institutes of Neurogenetics and Integrative and Experimental Genomics, University of Lübeck, Maria-Goeppert-Str. 1, MFC1, Lübeck, 23562, Germany, bertram.lars@gmail.com.

Abstract

For the first time in the history of human genetics research, it is now both technically feasible and economically affordable to screen individual genomes for novel disease-causing mutations at base-pair resolution using "next-generation sequencing" (NGS). One popular aim in many of today's NGS studies is genome resequencing (in part or whole) to identify DNA variants potentially accounting for the "missing heritability" problem observed in many genetically complex traits. Thus far, only relatively few projects have applied these powerful new technologies to search for novel Alzheimer's disease (AD) related sequence variants. In this review, I summarize the findings from the first NGS-based resequencing studies in AD and discuss their potential implications and limitations. Notable recent discoveries using NGS include the identification of rare susceptibility modifying alleles in APP, TREM2, and PLD3. Several other large-scale NGS projects are currently underway so that additional discoveries can be expected over the coming years.

PMID:
26235074
DOI:
10.1007/978-1-4939-2627-5_17
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center